ALNA News and Press, Allena Pharmaceuticals Inc. From 05/12/22

3 Penny Stocks to Watch in May 2022 With May at almost the halfway point, there are a lot of things that penny stocks traders need to understand. Right now, the major concerns surround rising inflation, climbing interest rates, and geopolitical tensions. All of this has led the stock ma...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lucid Motors (NASDAQ: LCID ) stock is on the move Thursday despite a lack of news from the electric vehicle (EV) company. Source: gg5795 / Shutterstock.com Without any news directly from the company, we’r...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allena Pharmaceuticals (NASDAQ: ALNA ) stock is rocketing higher on Thursday despite a lack of news from the company. Source: Shutterstock Instead, it looks like that movement is the result of heavy trading to...

The shares of Allena Pharmaceuticals (NASDAQ:ALNA), a development stage biotech with a focus on metabolic and kidney disorders have more than doubled in value in the pre-market Thursday on above average volume. More than 52 million Allena (ALNA) shares have changed hands so far, compared to t...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the start of another day comes our breakdown of the biggest pre-market stock movers and this time it’s for Thursday! Source: ventdusud / Shutterstock.com Earnings reports, heavy volume, and more have sto...

Buying Penny Stocks on May 9th? Here’s What You Need to Know If you’re looking for penny stocks to buy, there are hundreds of options to choose from. And after last week’s very volatile trading, many investors are unenthused about the state of the stock market right...

Allena Pharmaceuticals (NASDAQ:ALNA) enters a securities purchase agreement with an investor for the issuance and sale of an aggregate of ~1,436 shares of its Series D Convertible Preferred Stock, and ~1,436 shares of its Series E Convertible Preferred Stock in a registered direct o...

NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney dis...

B. Riley Securities has downgraded its recommendation for late-stage biotech, Allena Pharmaceuticals (ALNA +1.8%), to Neutral from Buy after the company announced its decision to halt the lead development program for reloxaliase. In a regulatory filing last week, Allena (NASDAQ:ALNA) said tha...

Late-stage biotech, Allena Pharmaceuticals (NASDAQ:ALNA), continues to trade lower with a decline of ~36% in the pre-market Monday after the company announced its decision to discontinue a Phase 3 trial for the lead candidate reloxaliase and highlighted its financial constraints. Following a ...